Eurofins Scientific SE : Technically solid
Entry price | Target | Stop-loss | Potential |
---|
€82.53 |
€88.49 |
€80.35 |
+7.22% |
---|
Shares in Eurofins Scientific SE do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Strengths● The group usually releases upbeat results with huge surprise rates.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● The tendency within the weekly time frame is positive above the technical support level at 68.63 EUR
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at EUR 88.21.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● With a 2021 P/E ratio at 29.8 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
● The company is not the most generous with respect to shareholders' compensation.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.